<![CDATA[Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial]]>

Дата публикации: 30-09-2026 18:29:04

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	<![CDATA[Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease]]>	0	14.69	15-10-2026
2	Sanofi Announces Decision Not to Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews	0	10.91	24-07-2026
3	Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies	0	22.47	16-07-2026
4	DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study	0	16.67	05-05-2026
5	FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2	0	19.68	29-06-2026
6	Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	0	13.95	26-06-2026
7	RANDOMIZED COMPARISON OF IBRUTINIB <i>VERSUS</i> OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL	0	2.29	27-08-2026
8	Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes	0	22.68	12-06-2026
9	A laser focus on melanoma	0	10	19-02-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 9.13. Источник: www.patientcareonline.com.